Using a Sequential Regimen to Eliminate Bacteria at Sublethal Antibiotic Dosages

被引:62
作者
Fuentes-Hernandez, Ayari [1 ]
Plucain, Jessica [2 ]
Gori, Fabio [2 ]
Pena-Miller, Rafael [1 ]
Reding, Carlos [2 ]
Jansen, Gunther [3 ]
Schulenburg, Hinrich [3 ]
Gudelj, Ivana [2 ]
Beardmore, Robert [2 ]
机构
[1] Univ Nacl Autonoma Mexico, Ctr Ciencias Genom, Cuernavaca 62191, Morelos, Mexico
[2] Univ Exeter, Biosci, Exeter, Devon, England
[3] Univ Kiel, Evolutionary Ecol & Genet, Kiel, Germany
基金
英国工程与自然科学研究理事会;
关键词
COLLATERAL SENSITIVITY; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; SUBINHIBITORY CONCENTRATIONS; HELICOBACTER-PYLORI; DRUG-RESISTANCE; GENE-EXPRESSION; THERAPY; COMBINATION; EVOLUTION;
D O I
10.1371/journal.pbio.1002104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We need to find ways of enhancing the potency of existing antibiotics, and, with this in mind, we begin with an unusual question: how low can antibiotic dosages be and yet bacterial clearance still be observed? Seeking to optimise the simultaneous use of two antibiotics, we use the minimal dose at which clearance is observed in an in vitro experimental model of antibiotic treatment as a criterion to distinguish the best and worst treatments of a bacterium, Escherichia coli. Our aim is to compare a combination treatment consisting of two synergistic antibiotics to so-called sequential treatments in which the choice of antibiotic to administer can change with each round of treatment. Using mathematical predictions validated by the E. coli treatment model, we show that clearance of the bacterium can be achieved using sequential treatments at antibiotic dosages so low that the equivalent two-drug combination treatments are ineffective. Seeking to treat the bacterium in testing circumstances, we purposefully study an E. coli strain that has a multidrug pump encoded in its chromosome that effluxes both antibiotics. Genomic amplifications that increase the number of pumps expressed per cell can cause the failure of high-dose combination treatments, yet, as we show, sequentially treated populations can still collapse. However, dual resistance due to the pump means that the antibiotics must be carefully deployed and not all sublethal sequential treatments succeed. A screen of 136 96-h-long sequential treatments determined five of these that could clear the bacterium at sublethal dosages in all replicate populations, even though none had done so by 24 h. These successes can be attributed to a collateral sensitivity whereby cross-resistance due to the duplicated pump proves insufficient to stop a reduction in E. coli growth rate following drug exchanges, a reduction that proves large enough for appropriately chosen drug switches to clear the bacterium.
引用
收藏
页数:17
相关论文
共 53 条
[41]   Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methichillin-resistant Staphylococcus aureus isolates [J].
Ohlsen, K ;
Ziebuhr, W ;
Koller, KP ;
Hell, W ;
Wichelhaus, TA ;
Hacker, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) :2817-2823
[42]   Strength of Selection Pressure Is an Important Parameter Contributing to the Complexity of Antibiotic Resistance Evolution [J].
Oz, Tugce ;
Guvenek, Aysegul ;
Yildiz, Sadik ;
Karaboga, Enes ;
Tamer, Yusuf Talha ;
Mumcuyan, Nirva ;
Ozan, Vedat Burak ;
Senturk, Gizem Hazal ;
Cokol, Murat ;
Yeh, Pamela ;
Toprak, Erdal .
MOLECULAR BIOLOGY AND EVOLUTION, 2014, 31 (09) :2387-2401
[43]   Drugs for bad bugs: confronting the challenges of antibacterial discovery [J].
Payne, David J. ;
Gwynn, Michael N. ;
Holmes, David J. ;
Pompliano, David L. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (01) :29-40
[44]   When the Most Potent Combination of Antibiotics Selects for the Greatest Bacterial Load: The Smile-Frown Transition [J].
Pena-Miller, Rafael ;
Laehnemann, David ;
Jansen, Gunther ;
Fuentes-Hernandez, Ayari ;
Rosenstiel, Philip ;
Schulenburg, Hinrich ;
Beardmore, Robert .
PLOS BIOLOGY, 2013, 11 (04)
[45]   Collateral sensitivity as a strategy against cancer multidrug resistance [J].
Pluchino, Kristen M. ;
Hall, Matthew D. ;
Goldsborough, Andrew S. ;
Callaghan, Richard ;
Gottesman, Michael M. .
DRUG RESISTANCE UPDATES, 2012, 15 (1-2) :98-105
[46]  
PolyMedix, 2013, BRIL PMX 30063 ANT F
[47]   Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections [J].
Proctor, RA ;
von Eiff, C ;
Kahl, BC ;
Becker, K ;
McNamara, P ;
Herrmann, M ;
Peters, G .
NATURE REVIEWS MICROBIOLOGY, 2006, 4 (04) :295-305
[48]   Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].
Rex, JH ;
Pfaller, MA ;
Galgiani, JN ;
Bartlett, MS ;
EspinelIngroff, A ;
Ghannoum, MA ;
Lancaster, M ;
Odds, FC ;
Rinaldi, MG ;
Walsh, TJ ;
Barry, AL .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247
[49]   Antibiotic resistance - What's dosing got to do with it? [J].
Roberts, Jason A. ;
Kruger, Peter ;
Paterson, David L. ;
Lipman, Jeffrey .
CRITICAL CARE MEDICINE, 2008, 36 (08) :2433-2440
[50]   Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus [J].
Sakoulas, George ;
Okumura, Cheryl Y. ;
Thienphrapa, Wdee ;
Olson, Joshua ;
Nonejuie, Poochit ;
Quang Dam ;
Dhand, Abhay ;
Pogliano, Joseph ;
Yeaman, Michael R. ;
Hensler, Mary E. ;
Bayer, Arnold S. ;
Nizet, Victor .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2014, 92 (02) :139-149